The role of epigenomics in the neurodegeneration of ataxia-telangiectasia

Epigenomics

Volumn 7, Issue 2, 2015, Pages 137-141

  Li, Jiali ^a   Jiang, Dewei ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

ataxia telangiectasia; cell cycle reentry; classic II HDACs; EZH2; H3K27me3; HDAC4; histone acetylation; histone methylation; neurodegenerative diseases; polycomb repressive complex 2

Indexed keywords

HISTONE DEACETYLASE 4; HISTONE LYSINE METHYLTRANSFERASE; POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR EZH2; HDAC5 PROTEIN, MOUSE; HISTONE DEACETYLASE; POLYCOMB REPRESSIVE COMPLEX 2;

ATAXIA TELANGIECTASIA; ATM GENE; CELL CYCLE; CELL NUCLEUS; CYTOPLASM; DEGENERATIVE DISEASE; EPIGENETICS; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; ANIMAL; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY;

ANIMALS; ATAXIA TELANGIECTASIA; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; MICE; NERVE DEGENERATION; NEURONS; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84928889963     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.81     Document Type: Note

References (52)

1. Sedgwick RP, Boder E. Progressive ataxia in childhood with particular reference to ataxia-telangiectasia. Neurology 10, 705-715 (1960).
2. Boder E. Ataxia-telangiectasia: some historic, clinical and pathologic observations. Birth Defects Orig. Artic. Ser. 11(1), 255-270 (1975).
3. Bundey S. Clinical and genetic features of ataxiatelangiectasia. Int. J. Radiat. Biol. 66, S23-S29 (1994).
4. Lavin MF, Shiloh Y. Ataxia-telangiectasia: a multifaceted genetic disorder associated with defective signal transduction. Curr. Opin. Immunol. 8, 459-464 (1996).
5. Biton S, Barzilai A, Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair (Amst.) 7, 1028-1038 (2008).
6. Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753 (1995).
7. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
8. Dar I, Biton S, Shiloh Y, Barzilai A. Analysis of the ataxia telangiectasia mutated-mediated DNA damage response in murine cerebellar neurons. J. Neurosci. 26, 7767-7774 (2006).
9. Yang Y, Herrup K. Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. J. Neurosci. 25, 2522-2529 (2005).
10. Rimkus SA, Katzenberger RJ, Trinh AT et al. Mutations in string/CDC25 inhibit cell cycle re-entry and neurodegeneration in a Drosophila model of ataxia telangiectasia. Genes Dev. 22, 1205-1220 (2008).
11. Li J, Chen J, Vinters HV, Gatti RA, Herrup K. Stable brain ATM message and residual kinase-active ATM protein in ataxia-telangiectasia. J. Neurosci. 31, 7568-7577 (2011).
12. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8, 57-64 (2008).
13. Agis-Balboa RC, Pavelka Z, Kerimoglu C, Fischer A. Loss of HDAC5 impairs memory function: implications for Alzheimers disease. J. Alzheimers Dis. 31(1), 35-44 (2012).
14. Alagiakrishnan K, Gill SS, Fagarasanu A. Genetics and epigenetics of Alzheimers disease. Postgrad. Med. J. 88, 522-529 (2012).
15. Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H. Alzheimers disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. Curr. Alzheimer Res. 9, 563-573 (2012).
16. Barbash S, Soreq H. Threshold-independent meta-analysis of Alzheimers disease transcriptomes shows progressive changes in hippocampal functions, epigenetics and microRNA regulation. Curr. Alzheimer Res. 9, 425-435 (2012).
17. Bihaqi SW, Schumacher A, Maloney B, Lahiri DK, Zawia NH. Do epigenetic pathways initiate late onset al.zheimer disease (LOAD): towards a new paradigm. Curr. Alzheimer Res. 9, 574-588 (2012).
18. Coppieters N, Dragunow M. Epigenetics in Alzheimers disease: a focus on DNA modifications. Curr. Pharm. Des. 17, 3398-3412 (2011).
19. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 25, 1010-1022 (2011).
20. Konsoula Z, Barile FA. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J. Pharmacol. Toxicol. Methods 66(3), 215-220 (2012).
21. Kinney SR, Pradhan S. Ten eleven translocation enzymes and 5-hydroxymethylation in mammalian development and cancer. Adv. Exp. Med. Biol. 754, 57-79 (2013).
22. Kwok JB. Role of epigenetics in Alzheimers and Parkinsons disease. Epigenomics 2, 671-682 (2010).
23. Maekawa M, Watanabe Y. Epigenetics: relations to disease and laboratory findings. Curr. Med. Chem. 14, 2642-2653 (2007).
24. Kudo Y, Tateishi K, Yamamoto K et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103, 670-676 (2012).
25. Marques SC, Oliveira CR, Pereira CM, Outeiro TF. Epigenetics in neurodegeneration: a new layer of complexity. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 348-355 (2011).
26. Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol. 8, 1056-1072 (2009).
27. Chouliaras L, Rutten BP, Kenis G et al. Epigenetic regulation in the pathophysiology of Alzheimers disease. Prog. Neurobiol. 90, 498-510 (2010).
28. Ma DK, Marchetto MC, Guo JU et al. Epigenetic choreographers of neurogenesis in the adult mammalian brain. Nat. Neurosci. 13, 1338-1344 (2010).
29. Fagiolini M, Jensen CL, Champagne FA. Epigenetic influences on brain development and plasticity. Curr. Opin. Neurobiol. 19, 207-212 (2009).
30. Wang AH, Bertos NR, Vezmar M et al. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell. Biol. 19, 7816-7827 (1999).
31. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl Acad. Sci. USA 96, 4868-4873 (1999).
32. Darcy MJ, Calvin K, Cavnar K, Ouimet CC. Regional and subcellular distribution of HDAC4 in mouse brain. J. Comp. Neurol. 518, 722-740 (2010).
33. Majdzadeh N, Wang L, Morrison BE et al. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev. Neurobiol. 68, 1076-1092 (2008).
34. Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science 323, 256-259 (2009).
35. Youn HD, Grozinger CM, Liu JO. Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4. J. Biol. Chem. 275, 22563-22567 (2000).
36. Bolger TA, Yao TP. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci. 25, 9544-9553 (2005).
37. Li J, Chen J, Ricupero CL et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat. Med. 18, 783-790 (2012).
38. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155-164 (2004).
39. Juan AH, Derfoul A, Feng X et al. Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev. 25, 789-794 (2011).
40. Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
41. Wei Y, Chen YH, Li LY et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell. Biol. 13, 87-94 (2011).
42. Wu Z, Lee ST, Qiao Y et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 18 (11), 1771-1779 (2011).
43. Francis NJ, Follmer NE, Simon MD, Aghia G, Butler JD. Polycomb proteins remain bound to chromatin and DNA during DNA replication in vitro. Cell 137, 110-122 (2009).
44. Surface LE, Thornton SR, Boyer LA. Polycomb group proteins set the stage for early lineage commitment. Cell Stem Cell 7, 288-298 (2010).
45. Sawarkar R, Paro R. Interpretation of developmental signaling at chromatin: the Polycomb perspective. Dev. Cell 19, 651-661 (2010 ).
46. Pirrotta V. PcG complexes and chromatin silencing. Curr. Opin. Genet. Dev. 7, 249-258 (1997).
47. Hirabayashi Y, Suzki N, Tsuboi M et al. Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. Neuron 63, 600-613 (2009).
48. Sauvageau M, Sauvageau G. Polycomb group proteins: multifaceted regulators of somatic stem cells and cancer. Cell Stem Cell 7(3), 299-313 (2010 ).
49. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
50. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15, 57-67 (2004).
51. Sewalt RG, van der Vlag J, Gunster MJ et al. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol. Cell. Biol. 18, 3586-3595 (1998).
52. Li J, Hart RP, Mallimo EM et al. EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxiatelangiectasia. Nat. Neurosci. 16, 1745-1753 (2013).